Clik here to view.
Zafgen Unveils Target of its Experimental Obesity Drugs: Methionine...
When I first wrote about obesity drug development back in 2009 I talked with Zafgen, Inc., a biopharmaceutical company working to develop its own obesity medications. At the time, the company was...
View ArticleA Proton-Transporting Protein As An Obesity Drug Target
No matter how disappointing obesity drug research seems to be these days, I can’t resist a good story about a hot biological target in the obesity area. And if obesity isn’t a hot enough topic for you,...
View ArticleClik here to view.
Zafgen’s ZGN-433 shows promise for obesity- so what’s it look like?
Just in time to coincide with January’s massive uptick in gym-going, Cambridge, MA startup Zafgen has announced good news about its experimental weight-loss drug for severe obesity. The molecule,...
View ArticleFDA’s Woodcock Talks Obesity Drug Safety
Janet Woodcock, head of FDA’s drugs center, had a few things to say about obesity drugs at Monday’s Reuters Health Summit in New York. Some of her comments weren’t surprising. But some of them might...
View ArticleClik here to view.
Zafgen’s Obesity Drug Shows Promise, Gets Funding
Beloranib. ZGN-433 is the hemioxalate salt of this molecule. (Credit- WHO Drug Information) Zafgen, whose science has been the subject of much speculation on the Haystack (see earlier posts), has again...
View ArticleClik here to view.
The Tail’s The Thing – Alkylamine Ethers and Zafgen’s ZGN-433
While posting about the Zafgen obesity drug candidate yesterday, I was staring at the Markush structure we’d drawn for ZGN-433 when Carmen Drahl sent over a 2008 volume of the World Health Organization...
View ArticleHaystack 2011 Year-in-Review
Well, 2011 is in the books, and we here at The Haystack felt nostalgic for all the great chemistry coverage over this past year, both here and farther afield. Let’s hit the high points: 1. HCV Takes...
View ArticleCelgene & Avila Forge Permanent Ties
Today brought a spate of M&A activity in the biotech space, with Amgen unveiling a $1.2 billion bid for Micromet, and Celgene agreeing to pay up to $925 million for Avila Therapeutics. Both deals...
View Article